AAM
VYGR icon

Aberdeen Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Aberdeen Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,909
Closed -$177K – 758
2016
Q4 		$177K Buy
+13,909
New +$179K ﹤0.01% 737

Other funds holding VYGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aberdeen Asset Management's VYGR Position: Q1 2017 in Review

Aberdeen Asset Management sold out of Voyager Therapeutics (VYGR) in Q1 2017, closing a stake of 13,909 shares — an estimated $177K sold.

Aberdeen Asset Management first reported a position in VYGR in Q4 2016 and held it in 1 quarter. The position peaked at $177K in Q4 2016. 47 funds tracked by Wall St. Rank hold VYGR as of Q1 2017.

  • Aberdeen Asset Management reported no remaining Voyager Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Aberdeen Asset Management sold 13,909 Voyager Therapeutics shares in Q1 2017, an estimated $177K.
  • Aberdeen Asset Management first reported a position in Voyager Therapeutics in Q4 2016 and held it in 1 quarter.
  • Aberdeen Asset Management's Voyager Therapeutics position peaked at $177K in Q4 2016.
  • 47 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2017.

Based on Aberdeen Asset Management's 13F filing for Q1 2017, filed 10 May 2017.